81 related articles for article (PubMed ID: 3053997)
41. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.
Krause SW; Gastpar R; Andreesen R; Gross C; Ullrich H; Thonigs G; Pfister K; Multhoff G
Clin Cancer Res; 2004 Jun; 10(11):3699-707. PubMed ID: 15173076
[TBL] [Abstract][Full Text] [Related]
42. Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor.
Blay JY; Favrot MC; Negrier S; Combaret V; Chouaib S; Mercatello A; Kaemmerlen P; Franks CR; Philip T
Cancer Res; 1990 Apr; 50(8):2371-4. PubMed ID: 2317822
[TBL] [Abstract][Full Text] [Related]
43. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients.
Sosman JA; Fisher SG; Kefer C; Fisher RI; Ellis TM
Ann Oncol; 1994 May; 5(5):447-52. PubMed ID: 7521206
[TBL] [Abstract][Full Text] [Related]
44. Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study.
Punt KC; Jansen RL; De Mulder PH; Batchelor D; Galazka A; Bolhuis RL; Stoter G
J Immunother (1991); 1992 Nov; 12(4):277-84. PubMed ID: 1477079
[TBL] [Abstract][Full Text] [Related]
45. Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin-2.
Lotzová E; Savary CA; Schachner JR; Huh JO; McCredie K
Am J Hematol; 1991 Jun; 37(2):88-99. PubMed ID: 2069169
[TBL] [Abstract][Full Text] [Related]
46. Clinical trials of intrasplenic arterial infusion of interleukin-2 (IS-IL-2) to patients with advanced cancer.
Okuno K; Ohnishi H; Koh K; Shindo H; Yoshioka H; Yasutomi M
Biotherapy; 1992; 4(4):257-65. PubMed ID: 1622739
[TBL] [Abstract][Full Text] [Related]
47. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.
Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Levitt D; Fefer A
J Clin Oncol; 1988 Apr; 6(4):669-78. PubMed ID: 3258631
[TBL] [Abstract][Full Text] [Related]
48. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease.
Atkins MB; Gould JA; Allegretta M; Li JJ; Dempsey RA; Rudders RA; Parkinson DR; Reichlin S; Mier JW
J Clin Oncol; 1986 Sep; 4(9):1380-91. PubMed ID: 3489080
[TBL] [Abstract][Full Text] [Related]
49. Some mechanisms of immunosuppressive action of epinephrine in humans.
Malec P; Tchórzewski H; Markiewicz K; Zeman K; Baj Z; Nowak Z; Pokoca L
Allergol Immunopathol (Madr); 1989; 17(2):81-4. PubMed ID: 2528271
[TBL] [Abstract][Full Text] [Related]
50. Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.
Helfand SC; Soergel SA; MacWilliams PS; Hank JA; Sondel PM
Cancer Immunol Immunother; 1994 Aug; 39(2):84-92. PubMed ID: 8044833
[TBL] [Abstract][Full Text] [Related]
51. Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.
Kohler PC; Hank JA; Moore KH; Storer B; Bechhofer R; Hong R; Sondel PM
Cancer Invest; 1989; 7(3):213-23. PubMed ID: 2790538
[TBL] [Abstract][Full Text] [Related]
52. Immunotherapy with IL2 by constant infusion and weekly doxorubicin.
Paciucci PA; Bekesi JG; Ryder JS; Odchimar R; Chahinian PA; Holland JF
Am J Clin Oncol; 1991 Aug; 14(4):341-8. PubMed ID: 1830717
[TBL] [Abstract][Full Text] [Related]
53. Effects of two different hydrocortisone doses on human peripheral blood lymphocyte nucleologram.
Malacarne P; Marzola M; Santini A; Indelli M
Folia Biol (Praha); 1989; 35(1):13-8. PubMed ID: 2714498
[TBL] [Abstract][Full Text] [Related]
54. In vivo amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients.
Provinciali M; Ciavattini A; Di Stefano G; Argentati K; Garzetti GG
Life Sci; 1999; 64(17):1525-32. PubMed ID: 10353617
[TBL] [Abstract][Full Text] [Related]
55. Interleukin-4 affects phenotype and proliferative response of peripheral blood lymphocytes from glioblastoma patients after specific or nonspecific in vitro stimulation.
Faber C; Sandt G; Dang PT; Matgé G; Schiltz F; Heuschling P
J Immunother Emphasis Tumor Immunol; 1994 Feb; 15(2):113-8. PubMed ID: 8136943
[TBL] [Abstract][Full Text] [Related]
56. Functional Activity of Lymphocytes of Healthy Donors and Cancer Patients After Culturing with IL-2 and IL-15.
Gel'm YV; Kuz'mina EG; Abakushina EV
Bull Exp Biol Med; 2019 Aug; 167(4):486-491. PubMed ID: 31494764
[TBL] [Abstract][Full Text] [Related]
57. Different individual immune responses elicited by in vitro immunization.
Yamashita M; Katakura Y; Shim SY; Matsumoto SE; Tamura T; Morihara K; Aiba Y; Teruya K; Tsuchiya T; Shirahata S
Cytotechnology; 2002 Nov; 40(1-3):161-5. PubMed ID: 19003117
[TBL] [Abstract][Full Text] [Related]
58. Chromatin isolated from viable human PBLs contains DNA fragmented to >/=50 kb.
Szabó G; Bacsó Z
Cell Death Differ; 1996 Apr; 3(2):237-41. PubMed ID: 17180088
[TBL] [Abstract][Full Text] [Related]
59. Isolation of lymphocytes from clotted blood.
Niku SD; Hoon DS; Cochran AJ; Morton DL
J Immunol Methods; 1987 Dec; 105(1):9-14. PubMed ID: 3680965
[TBL] [Abstract][Full Text] [Related]
60. Stabilization and enhancement of interleukin-2 in vitro bioactivity by new carriers: supramolecular biovectors.
Castignolles N; Betbeder D; Ioualalen K; Merten O; Leclerc C; Samain D; Perrin P
Vaccine; 1994 Nov; 12(15):1413-8. PubMed ID: 7887019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
